Laurus Labs Limited

rs,

October 21, 2022 To To The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25th Floor, Dalal Street Mumbai – 400001 The Listing Department National Stock Exchange of Indi

₹ 3,115

n | July 27, 2022 1H/FY23 – Overview Strong Performance in a challenging environment Revenues ₹ 3,115 Cr ▲26% EBITDA ₹ 903 Cr ▲ 21% Summary 1H/FY23 Consolidated Financials 1H/FY23 1H/FY22 Y-o-Y

26%

2022 1H/FY23 – Overview Strong Performance in a challenging environment Revenues ₹ 3,115 Cr ▲26% EBITDA ₹ 903 Cr ▲ 21% Summary 1H/FY23 Consolidated Financials 1H/FY23 1H/FY22 Y-o-Y Synth

₹ 903

– Overview Strong Performance in a challenging environment Revenues ₹ 3,115 Cr ▲26% EBITDA ₹ 903 Cr ▲ 21% Summary 1H/FY23 Consolidated Financials 1H/FY23 1H/FY22 Y-o-Y Synthesis business 

21%

Strong Performance in a challenging environment Revenues ₹ 3,115 Cr ▲26% EBITDA ₹ 903 Cr ▲ 21% Summary 1H/FY23 Consolidated Financials 1H/FY23 1H/FY22 Y-o-Y Synthesis business  Strong m

56.3%

th, driven by [₹Crore] Revenues Gross Margins EBITDA % to Revenues Net Profit EPS 3,115 56.3% 903 29.0% 484 9.0 2,482 56.2% 748 26% 10bps 21% 30.1% -110bps 443 8.2 1H/FY23 1H/FY

29.0%

y [₹Crore] Revenues Gross Margins EBITDA % to Revenues Net Profit EPS 3,115 56.3% 903 29.0% 484 9.0 2,482 56.2% 748 26% 10bps 21% 30.1% -110bps 443 8.2 1H/FY23 1H/FY22 Operatin

56.2%

Gross Margins EBITDA % to Revenues Net Profit EPS 3,115 56.3% 903 29.0% 484 9.0 2,482 56.2% 748 26% 10bps 21% 30.1% -110bps 443 8.2 1H/FY23 1H/FY22 Operating Cash flow Capex Net

10bps

BITDA % to Revenues Net Profit EPS 3,115 56.3% 903 29.0% 484 9.0 2,482 56.2% 748 26% 10bps 21% 30.1% -110bps 443 8.2 1H/FY23 1H/FY22 Operating Cash flow Capex Net Debt-to-EBITDA

30.1%

Revenues Net Profit EPS 3,115 56.3% 903 29.0% 484 9.0 2,482 56.2% 748 26% 10bps 21% 30.1% -110bps 443 8.2 1H/FY23 1H/FY22 Operating Cash flow Capex Net Debt-to-EBITDA 243 416 1.

110bps

Net Profit EPS 3,115 56.3% 903 29.0% 484 9.0 2,482 56.2% 748 26% 10bps 21% 30.1% -110bps 443 8.2 1H/FY23 1H/FY22 Operating Cash flow Capex Net Debt-to-EBITDA 243 416 1.1X 315

1.1X

1% -110bps 443 8.2 1H/FY23 1H/FY22 Operating Cash flow Capex Net Debt-to-EBITDA 243 416 1.1X 315 455 1.1x ROCE 27.9% 28.8% -0.9%pts 5 Laurus Q2 & H1 FY2023 Investor Presentation | Oct

New technology forayed

1

New technology forayed

Recombinant Proteins (FY21) CAR-T Cell therapy (FY22)  Retain FY25/26 goal of ~25% revenues from Synthesis Continued Organic Investment in manufacturing asset, Integrated approach across portfolio, Strong quality and leadership team * Adjusting for exceptional revenues in Hep C segment, ARV: Anti-Retroviral 23 Laurus Q2 & H1 FY2023 Investor Presentation | October 21, 2022 ARV api *80%Onco & Other APIs, 16%Synthesis, 19%FDF, 38%ARV apis, 25%Bio, 2% Outlook FY2023 & year ahead Business Segments Business Segments Growth Outlook Formulations  Consolidate market share gains in ARV portfolio despite continued pricing challenges  Creating niche product pipeline for the developed markets backed by in-house API strength  Strong DM pipeline >US$40bn mkt opportunity; Diabetic & CV portfolio monetization from FY23  Brownfield Scale up API demand based capacity expansion  Enhance positioning on HP APIs & Scaling up of Anti-diabetic, CV & PPI portfolio supported by  Maintain ARV API leadershi